Rosen Law Firm Investigates Disc Medicine
Analysis based on 68 articles · First reported Apr 29, 2026 · Last updated Aug 22, 2026
The investigation by Rosen Law Firm into Disc Medicine, Inc. for allegedly misleading business information could lead to a class action lawsuit, potentially resulting in significant financial liabilities for Disc Medicine and further impacting its stock price negatively. Investors who purchased Disc Medicine securities may be entitled to compensation, which could affect investor confidence in the biotechnology sector.
Rosen Law Firm is continuing its investigation into Disc Medicine, Inc. following a Complete Response Letter issued by the United States — Food and Drug Administration on February 13, 2026, concerning Disc Medicine's bitopertin program. The United States — Food and Drug Administration cited uncertainties in the new drug application, which led to a 22% drop in Disc Medicine's stock price on the day of the announcement. Rosen Law Firm is preparing a class action lawsuit to recover investor losses, alleging that Disc Medicine may have issued materially misleading business information to the investing public.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard